top of page

Other References

  1. Related to QTsome, WGI-0301, WGI-2101: https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.5b00878

  2. Related to WGI-0401: https://www.oncotarget.com/article/8871/text/

  3. QTsome/AM-21 Mouse Study: https://pubmed.ncbi.nlm.nih.gov/26741162/

  4. AM-21 Therapeutics Review: https://pubmed.ncbi.nlm.nih.gov/32244168/

  5. AM-21 Review: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5038362/

  6. Bortezomib P2 Clinical Trial: https://www.nejm.org/doi/full/10.1056/NEJMoa030288

  7. Liposomal Bortezomib Mouse Study: https://pubmed.ncbi.nlm.nih.gov/27144331/

  8. Bortezomib for Multiple Myeloma Review: https://pubmed.ncbi.nlm.nih.gov/24395544/

  9. Abraxane P3 Clinical Trial: https://ascopubs.org/doi/10.1200/JCO.2005.04.937

  10. Abraxane with Gemcitabine P3 Clinical Trial: https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.4000

  11. Abraxane Metastatic Breast Cancer Review: https://www.nature.com/articles/s41598-019-57380-0

bottom of page